Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $628.28 billion. The enterprise value is $630.82 billion.
| Market Cap | 628.28B |
| Enterprise Value | 630.82B |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, before market open.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | Mar 22, 2024 |
Share Statistics
Novo Nordisk has 4.39 billion shares outstanding.
| Shares Outstanding | 4.39B |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 9.74% |
| Float | 3.19B |
Valuation Ratios
The trailing PE ratio is 50.00 and the forward PE ratio is 39.53. Novo Nordisk's PEG ratio is 2.36.
| PE Ratio | 50.00 |
| Forward PE | 39.53 |
| PS Ratio | 17.78 |
| Forward PS | 2.03 |
| PB Ratio | 44.09 |
| P/FCF Ratio | 68.32 |
| PEG Ratio | 2.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 35.64, with an EV/FCF ratio of 68.60.
| EV / Earnings | 48.83 |
| EV / Sales | 17.85 |
| EV / EBITDA | 35.64 |
| EV / EBIT | 39.01 |
| EV / FCF | 68.60 |
Financial Position
The company has a current ratio of 0.70, with a Debt / Equity ratio of 0.27.
| Current Ratio | 0.70 |
| Quick Ratio | 0.40 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 0.22 |
| Debt / FCF | 0.42 |
| Interest Coverage | 296.91 |
Financial Efficiency
Return on equity (ROE) is 91.80% and return on invested capital (ROIC) is 69.40%.
| Return on Equity (ROE) | 91.80% |
| Return on Assets (ROA) | 29.90% |
| Return on Capital (ROIC) | 69.40% |
| Revenue Per Employee | $549,547 |
| Profits Per Employee | $200,871 |
| Employee Count | 64,319 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 1.27 |
Taxes
In the past 12 months, Novo Nordisk has paid $3.25 billion in taxes.
| Income Tax | 3.25B |
| Effective Tax Rate | 20.12% |
Stock Price Statistics
The stock price has increased by +79.36% in the last 52 weeks. The beta is 0.17, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +79.36% |
| 50-Day Moving Average | 135.23 |
| 200-Day Moving Average | 115.72 |
| Relative Strength Index (RSI) | 56.10 |
| Average Volume (20 Days) | 3,710,299 |
Short Selling Information
| Short Interest | 4.48M |
| Short Previous Month | 3.71M |
| Short % of Shares Out | 0.14% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.27 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $35.35 billion and earned $12.92 billion in profits. Earnings per share was $2.87.
| Revenue | 35.35B |
| Gross Profit | 29.79B |
| Operating Income | 15.76B |
| Pretax Income | 16.12B |
| Net Income | 12.92B |
| EBITDA | 17.70B |
| EBIT | 16.17B |
| Earnings Per Share (EPS) | $2.87 |
Balance Sheet
The company has $1.34 billion in cash and $3.88 billion in debt, giving a net cash position of -$2.54 billion or -$0.58 per share.
| Cash & Cash Equivalents | 1.34B |
| Total Debt | 3.88B |
| Net Cash | -2.54B |
| Net Cash Per Share | -$0.58 |
| Equity (Book Value) | 14.25B |
| Book Value Per Share | 3.24 |
| Working Capital | -7.09B |
Cash Flow
In the last 12 months, operating cash flow was $13.46 billion and capital expenditures -$4.26 billion, giving a free cash flow of $9.20 billion.
| Operating Cash Flow | 13.46B |
| Capital Expenditures | -4.26B |
| Free Cash Flow | 9.20B |
| FCF Per Share | $2.04 |
Margins
Gross margin is 84.28%, with operating and profit margins of 44.60% and 36.55%.
| Gross Margin | 84.28% |
| Operating Margin | 44.60% |
| Pretax Margin | 45.60% |
| Profit Margin | 36.55% |
| EBITDA Margin | 50.07% |
| EBIT Margin | 45.75% |
| FCF Margin | 26.02% |
Dividends & Yields
This stock pays an annual dividend of $0.67, which amounts to a dividend yield of 0.47%.
| Dividend Per Share | $0.67 |
| Dividend Yield | 0.47% |
| Dividend Growth (YoY) | 3,334.59% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 23.54% |
| Buyback Yield | 1.10% |
| Shareholder Yield | 1.57% |
| Earnings Yield | 2.06% |
| FCF Yield | 1.46% |
Analyst Forecast
The average price target for Novo Nordisk is $140.50, which is -1.73% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $140.50 |
| Price Target Difference | -1.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 15.83% |
| EPS Growth Forecast (5Y) | 16.68% |
Stock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 15.41 and a Piotroski F-Score of 8.
| Altman Z-Score | 15.41 |
| Piotroski F-Score | 8 |